These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 11451955)

  • 1. Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects.
    Thirunavukkarasu K; Miles RR; Halladay DL; Yang X; Galvin RJ; Chandrasekhar S; Martin TJ; Onyia JE
    J Biol Chem; 2001 Sep; 276(39):36241-50. PubMed ID: 11451955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The osteoblast-specific transcription factor Cbfa1 contributes to the expression of osteoprotegerin, a potent inhibitor of osteoclast differentiation and function.
    Thirunavukkarasu K; Halladay DL; Miles RR; Yang X; Galvin RJ; Chandrasekhar S; Martin TJ; Onyia JE
    J Biol Chem; 2000 Aug; 275(33):25163-72. PubMed ID: 10833509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transforming growth factor-beta stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells.
    Takai H; Kanematsu M; Yano K; Tsuda E; Higashio K; Ikeda K; Watanabe K; Yamada Y
    J Biol Chem; 1998 Oct; 273(42):27091-6. PubMed ID: 9765225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of stromal cell RANKL, OPG, and M-CSF expression in biphasic TGF-beta regulation of osteoclast differentiation.
    Karst M; Gorny G; Galvin RJ; Oursler MJ
    J Cell Physiol; 2004 Jul; 200(1):99-106. PubMed ID: 15137062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptional mechanisms of bone morphogenetic protein-induced osteoprotegrin gene expression.
    Wan M; Shi X; Feng X; Cao X
    J Biol Chem; 2001 Mar; 276(13):10119-25. PubMed ID: 11139569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.
    Quinn JM; Itoh K; Udagawa N; Hausler K; Yasuda H; Shima N; Mizuno A; Higashio K; Takahashi N; Suda T; Martin TJ; Gillespie MT
    J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation.
    Lee SK; Lorenzo JA
    Endocrinology; 1999 Aug; 140(8):3552-61. PubMed ID: 10433211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells.
    Kondo H; Guo J; Bringhurst FR
    J Bone Miner Res; 2002 Sep; 17(9):1667-79. PubMed ID: 12211438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of osteoprotegerin expression by prostaglandin E2 is crucially involved in lipopolysaccharide-induced osteoclast formation.
    Suda K; Udagawa N; Sato N; Takami M; Itoh K; Woo JT; Takahashi N; Nagai K
    J Immunol; 2004 Feb; 172(4):2504-10. PubMed ID: 14764723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of signal transduction pathways and promoter sequences that mediate parathyroid hormone 1-38 inhibition of osteoprotegerin gene expression.
    Halladay DL; Miles RR; Thirunavukkarasu K; Chandrasekhar S; Martin TJ; Onyia JE
    J Cell Biochem; 2001; 84(1):1-11. PubMed ID: 11746511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nitric oxide donor increases osteoprotegerin production and osteoclastogenesis inhibitory activity in bone marrow stromal cells from ovariectomized rats.
    Wang FS; Wang CJ; Chen YJ; Huang YT; Huang HC; Chang PR; Sun YC; Yang KD
    Endocrinology; 2004 May; 145(5):2148-56. PubMed ID: 14962990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vector-averaged gravity regulates gene expression of receptor activator of NF-kappaB (RANK) ligand and osteoprotegerin in bone marrow stromal cells via cyclic AMP/protein kinase A pathway.
    Kanematsu M; Yoshimura K; Takaoki M; Sato A
    Bone; 2002 Apr; 30(4):553-8. PubMed ID: 11934645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipopolysaccharide from Prevotella nigrescens stimulates osteoclastogenesis in cocultures of bone marrow mononuclear cells and primary osteoblasts.
    Chung YH; Chang EJ; Kim SJ; Kim HH; Kim HM; Lee SB; Ko JS
    J Periodontal Res; 2006 Aug; 41(4):288-96. PubMed ID: 16827722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTH differentially regulates expression of RANKL and OPG.
    Huang JC; Sakata T; Pfleger LL; Bencsik M; Halloran BP; Bikle DD; Nissenson RA
    J Bone Miner Res; 2004 Feb; 19(2):235-44. PubMed ID: 14969393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts.
    Takami M; Takahashi N; Udagawa N; Miyaura C; Suda K; Woo JT; Martin TJ; Nagai K; Suda T
    Endocrinology; 2000 Dec; 141(12):4711-9. PubMed ID: 11108286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transforming growth factor-beta1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells.
    Murakami T; Yamamoto M; Ono K; Nishikawa M; Nagata N; Motoyoshi K; Akatsu T
    Biochem Biophys Res Commun; 1998 Nov; 252(3):747-52. PubMed ID: 9837778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
    Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
    J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
    Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
    J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
    Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T
    J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.